Review Process

All submissions are evaluated by a double-blind, peer-review process. Prior to dissemination to the reviewers, the Editor will conduct a preliminary appraisal for content, substance, and appropriateness to the journal. Review is carried out by two reviewers from different affiliates. If the manuscript is clearly inappropriate, the author will be informed and the manuscript returned. Appropriate manuscripts will be sent to two reviewers for blind evaluation. Although there is an attempt to match manuscripts and reviewers according to content, interests, and topical relevance, the broad focus of the journal dictates that papers be written for applicability to a wide audience. The Editor shall inform you of the results of the review as soon as possible, hopefully in 3 months. The final decision is taken by one of the senior editors based on the information gained through the peer review process.

• Accepted, as it is
• Accepted by Minor Revisions(let authors revised with stipulated time)
• Accepted by Major Revisions(let authors revised with stipulated time)
• Declined(generally, on grounds of outside of scope and aim, major technical description problems, lack of clarity of presentation)

For checking Plagiarism, Jurnal Farmasi Indonesia AFAMEDIS Editorial Board will screen plagiarism using Plagiarism Checker 25%. If it is found plagiarism indication, editorial board will reject manuscript immediately.

Decline

Following peer review, the paper is judged not to be acceptable for publication in Jurnal Farmasi Indonesia AFAMEDIS and resubmission is not possible.

Resubmit for Review

The submitted version of the paper is not acceptable and requires major revision but there is clear potential in the work and Jurnal Farmasi Indonesia AFAMEDIS is prepared to consider a new version. Authors are offered the opportunity to resubmit their paper as a new submission. Concerns will remain regarding the suitability of the paper for publication until the editors are convinced by the authors that their paper fits the scope and standards of Jurnal Farmasi Indonesia AFAMEDIS. The resubmitted manuscript will be returned to the original associate editor if at all possible.

Revision

The paper requires changes before a final decision can be made. Authors are asked to modify their manuscript in light of comments received from referees and editors and to submit a new version for consideration within 2 weeks of receiving the decision letter. A point-by-point explanation of how comments have been addressed must be supplied with the revised version of the paper. Revisions may undergo further peer review and papers may undergo more than one round of revision. If the authors do not revise their papers to the satisfaction of the editors, the paper can still be declined from publication in Jurnal Farmasi Indonesia AFAMEDIS.

Accept Submission

The paper is accepted for publication, subject to conditions that need to be addressed in producing a final version of the manuscript. These may include sub-editing changes and minor amendment to ensure the paper fully matches our criteria. After final checking in the editorial office, acceptance is confirmed and the paper is forwarded to the publishers for publication.

Before publishing, it is required to obtain written confirmation from authors in order to acquire copyrights for papers published in the journal. Authors must sign the Copyright Transfer Form as follows: The undersigned hereby transfer any and all rights in and to the paper including without limitation all copyrights to Jurnal Farmasi Indonesia AFAMEDIS. The undersigned hereby represents and warrants that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required. The undersigned represents that he/she has the power and authority to make and execute this assignment. This agreement is to be signed by at least one of the authors who have obtained the assent of the co-author(s) where applicable.